Annual CFF
$125.97 M
+$53.18 M+73.06%
31 December 2023
Summary:
Inozyme Pharma annual cash flow from financing activities is currently $125.97 million, with the most recent change of +$53.18 million (+73.06%) on 31 December 2023. During the last 3 years, it has fallen by -$23.84 million (-15.92%). INZY annual CFF is now -15.92% below its all-time high of $149.81 million, reached on 31 December 2020.INZY Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$10.52 M
+$10.06 M+2197.60%
30 September 2024
Summary:
Inozyme Pharma quarterly cash flow from financing activities is currently $10.52 million, with the most recent change of +$10.06 million (+2197.60%) on 30 September 2024. Over the past year, it has dropped by -$59.19 million (-84.91%). INZY quarterly CFF is now -91.15% below its all-time high of $118.86 million, reached on 30 September 2020.INZY Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$23.66 M
-$59.19 M-71.45%
30 September 2024
Summary:
Inozyme Pharma TTM cash flow from financing activities is currently $23.66 million, with the most recent change of -$59.19 million (-71.45%) on 30 September 2024. Over the past year, it has dropped by -$89.80 million (-79.15%). INZY TTM CFF is now -84.31% below its all-time high of $150.81 million, reached on 30 September 2020.INZY TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INZY Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +73.1% | -84.9% | -79.2% |
| 3 y3 years | -15.9% | +4340.1% | +6196.9% |
| 5 y5 years | +294.3% | +10000.0% | +3.0% |
INZY Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -15.9% | >+9999.0% | -84.9% | -81.2% | +6196.9% | |
| 5 y | 5 years | -15.9% | >+9999.0% | -91.2% | +1167.2% | -84.3% | +6196.9% |
| alltime | all time | -15.9% | >+9999.0% | -91.2% | +1167.2% | -84.3% | +6196.9% |
Inozyme Pharma Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $10.52 M(+2197.6%) | $23.66 M(-71.4%) |
| June 2024 | - | $458.00 K(+188.1%) | $82.85 M(-21.9%) |
| Mar 2024 | - | $159.00 K(-98.7%) | $106.03 M(-15.8%) |
| Dec 2023 | $125.97 M(+73.1%) | $12.52 M(-82.0%) | $125.97 M(+11.0%) |
| Sept 2023 | - | $69.72 M(+194.9%) | $113.45 M(+136.6%) |
| June 2023 | - | $23.64 M(+17.6%) | $47.95 M(-48.2%) |
| Mar 2023 | - | $20.10 M(>+9900.0%) | $92.64 M(+27.3%) |
| Dec 2022 | $72.79 M(>+9900.0%) | $0.00(-100.0%) | $72.79 M(-0.0%) |
| Sept 2022 | - | $4.21 M(-93.8%) | $72.80 M(+5.8%) |
| June 2022 | - | $68.33 M(>+9900.0%) | $68.82 M(>+9900.0%) |
| Mar 2022 | - | $240.00 K(+2081.8%) | $600.00 K(-1.5%) |
| Dec 2021 | $609.00 K | $11.00 K(-95.4%) | $609.00 K(-257.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | $237.00 K(+111.6%) | -$388.00 K(-100.3%) |
| June 2021 | - | $112.00 K(-55.0%) | $118.24 M(-21.2%) |
| Mar 2021 | - | $249.00 K(-125.3%) | $150.06 M(+0.2%) |
| Dec 2020 | $149.81 M(+552.2%) | -$986.00 K(-100.8%) | $149.81 M(-0.7%) |
| Sept 2020 | - | $118.86 M(+272.2%) | $150.81 M(+371.6%) |
| June 2020 | - | $31.93 M(>+9900.0%) | $31.98 M(>+9900.0%) |
| Mar 2020 | - | $5000.00(-44.4%) | $43.00 K(-99.8%) |
| Dec 2019 | $22.97 M(-28.1%) | $9000.00(-69.0%) | $22.97 M(+0.0%) |
| Sept 2019 | - | $29.00 K(>+9900.0%) | $22.96 M(+0.1%) |
| June 2019 | - | $0.00(-100.0%) | $22.93 M(0.0%) |
| Mar 2019 | - | $22.93 M | $22.93 M |
| Dec 2018 | $31.95 M | - | - |
FAQ
- What is Inozyme Pharma annual cash flow from financing activities?
- What is the all time high annual CFF for Inozyme Pharma?
- What is Inozyme Pharma annual CFF year-on-year change?
- What is Inozyme Pharma quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Inozyme Pharma?
- What is Inozyme Pharma quarterly CFF year-on-year change?
- What is Inozyme Pharma TTM cash flow from financing activities?
- What is the all time high TTM CFF for Inozyme Pharma?
- What is Inozyme Pharma TTM CFF year-on-year change?
What is Inozyme Pharma annual cash flow from financing activities?
The current annual CFF of INZY is $125.97 M
What is the all time high annual CFF for Inozyme Pharma?
Inozyme Pharma all-time high annual cash flow from financing activities is $149.81 M
What is Inozyme Pharma annual CFF year-on-year change?
Over the past year, INZY annual cash flow from financing activities has changed by +$53.18 M (+73.06%)
What is Inozyme Pharma quarterly cash flow from financing activities?
The current quarterly CFF of INZY is $10.52 M
What is the all time high quarterly CFF for Inozyme Pharma?
Inozyme Pharma all-time high quarterly cash flow from financing activities is $118.86 M
What is Inozyme Pharma quarterly CFF year-on-year change?
Over the past year, INZY quarterly cash flow from financing activities has changed by -$59.19 M (-84.91%)
What is Inozyme Pharma TTM cash flow from financing activities?
The current TTM CFF of INZY is $23.66 M
What is the all time high TTM CFF for Inozyme Pharma?
Inozyme Pharma all-time high TTM cash flow from financing activities is $150.81 M
What is Inozyme Pharma TTM CFF year-on-year change?
Over the past year, INZY TTM cash flow from financing activities has changed by -$89.80 M (-79.15%)